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A B S T R A C T
Angiogenesis is a hallmark of cancer and a requisite that tumors must achieve to fulﬁll their metabolic needs of
nutrients and oxygen. As a critical step in cancer progression, the ‘angiogenic switch’ allows tumor cells to
survive and grow, and provides them access to vasculature resulting in metastatic progression and dissemina-
tion. Tumor-dependent triggering of the angiogenic switch has critical consequences on tumor progression
which extends from an increased nutrient supply and relies instead on the ability of the tumor to hijack the host
immune response for the generation of a local immunoprivileged microenvironment. Tumor angiogenic-medi-
ated establishment of endothelial anergy is responsible for this process. However, tumor endothelium can also
promote immune tolerance by unbalanced expression of co-stimulatory and co-inhibitory molecules and by
releasing soluble factors that restrain T cell function and induce apoptosis. In this review, we discuss the mo-
lecular properties of the tumor endothelial barrier and endothelial anergy and discuss the main im-
munosuppressive mechanisms triggered by the tumor endothelium. Lastly, we describe the current anti-angio-
genic therapeutic landscape and how targeting tumor angiogenesis can contribute to improve clinical beneﬁts
for patients.
1. Introduction
1.1. The angiogenic switch
The proliferation of every normal cell in our body is ﬁnely tuned by
a network of growth-promoting and inhibitory mechanisms, in the form
of soluble factors, physical stress and cell–cell interactions. When
homeostatic control succumbs or is hijacked, the cell fails to continue as
master of its own destiny within the tissue architecture. Unregulated
proliferation and resistance to apoptosis represent two of the ﬁrst cri-
tical events in tumor transformation; afterwards, tumor progressively
evolves, driven by genomic instability, which in turn promotes acqui-
sition of new functions and sculpts anti-tumor immunity in a process
called “cancer immunoediting” [1,2]. The contribution of the immune
system to tumor evolution reﬂects a double-edged sword that restricts
tumor growth in the elimination and equilibrium phases of cancer but
eventually succumbs to tumor modulation by supporting cancer pro-
gression and metastatic spread during the escape phase. According to
this hypothesis, tumors cannot be considered merely a mass of neo-
plastic and polarized stromal cells but rather a conductor, which ex-
ploits physiological immune regulatory mechanisms to generate per-
ipheral and local immune tolerance, establishing a tumor-promoting
microenvironment that supports its own growth and ability to metas-
tasize.
Neoplastic cells are characterized by speciﬁc hallmarks including
undeﬁned proliferation, evasion of growth suppressors, replicative
immortality, resistance to cell death, invasive properties and ability to
manipulate the local microenvironment by inducing angiogenesis and
promoting immune system evasion [3]. Within blood vessel generation,
vasculogenesis (assembly of the de novo vasculature assisted by re-
cruitment of endothelial progenitors cells) and angiogenesis (sprouting
of new vasculature from already established vessels, a process guided
by proliferation of endothelial cells – ECs) are both active during or-
ganogenesis. Angiogenesis predominates in the adult and this term was
introduced more than 200 years ago by the surgeon John Hunter to
describe the growth of new blood vessels during tissue development in
adult animals [4]. However, the players involved in angiogenesis and
its role in promoting cancer progression were described quite recently
by Judah Folkman [5] and then characterized by others [6,7]. Under
physiological state, the endothelium is in a quiescent condition, main-
tained by a ﬁnely-tuned homeostatic process, that can be interrupted
periodically (e.g. during female reproductive cycle), either by a reduc-
tion in angiostatic molecules or an increase in angiogenic factors ac-
cording to the requirements of each body tissue. In each of these cases,
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after local basal membrane degradation, ECs change shape and begin
proliferating by sensing a gradient of pro-angiogenic signals, invading
the surrounding stroma and generating new capillaries. Primary an-
giogenic mediators include the vascular endothelial growth factor
(VEGF) family proteins, ﬁbroblast growth factors (FGF), platelet-de-
rived growth factor (PDGF), placental growth factor (PlGF), angio-
poietin (ANG) 2, chemokines and cytokines such as chemokine (C-X-C
motif) ligand (CXCL)8, tumor necrosis factor (TNF) α, interleukin (IL)
1β, tumor growth factor (TGF) β, prokineticin (BV8), and matrix me-
talloproteases (MMPs). Angiogenesis is restricted by several molecules
with angiostatic properties such as thrombospondin (TSP) 1, angios-
tatin, soluble VEGF1, endostatin, vasostatin, calreticulin, tissue in-
hibitor of metalloproteases (TIMPs), as well as cytokines such as in-
terferon (IFN)γ, IFN-induced cytokines binding CXCR3 (CXCL9/MIG,
CXCL10/IP10, CXCL11/IP9) [8], and others [9]. The expression of
angiogenic factors is ﬁnely tuned by local oxygen levels through hy-
poxia inducible factor (HIF). This protein is a heterodimer composed by
HIF1α and HIF1β able to activate the expression of genes through the
binding to hypoxia response element (HRE) sequences placed in their
promoter regions. Both subunits are constitutively expressed but HIF1α
is quickly hydroxylated under normoxic conditions [10], ubiquitinated
and degraded after translation [11]. Once a tumor reaches the size of
few millimeters, the simple diﬀusion of oxygen and nutrients from the
surrounding tissue is not suﬃcient to support cell growth. This results
in a condition of low oxygen concentration that stabilizes HIF1α which
can then enter the nucleus, dimerize with HIF1β, and trigger the ex-
pression of many angiogenic factors (VEGFs, PDGFB, PlGF, ANGPTs)
[12], proangiogenic chemokines (stromal cell derived factor 1α -
SDF1α/CXCL12 and sphingosine 1 phosphate) and receptors (CXCR4
and sphingosine 1 phosphate receptor) [13], the so called “angiogenic
switch”. This process generates chronic endothelium activation, which
results in continuous sprouting of new vessels supporting tumor growth
[14]. Induction of angiogenesis represents an early event during tu-
morigenesis [15] for two biological reasons: an elevated proliferation
rate requires high consumption of nutrients and oxygen and removal of
toxic metabolic products, both duties performed by blood circulation.
Furthermore, proliferative switches (e.g. RAF and RAS activation) in-
duce activation of the angiogenic program [16,17]. VEGF members
include VEGFA, VEGFB, VEGFC, VEGFD and PlGF and exert their an-
giogenic functions by interacting with the VEGF receptors (VEGFRs).
VEGFRs are tyrosine kinase receptors (TKRs) that bind each of these
ligands, triggering a tyrosine kinase-based signaling cascade: VEGFR1 is
triggered by VEGFB and PlGF to induce haematopoiesis, monocyte
migration, and EC metabolism, whereas VEGFR2 is activated following
VEGFA binding to induce EC proliferation, survival, angiogenesis and
vascular permeability. VEGFC and VEGFD are involved in activating
lymphangiogenesis (proliferation of lymphatic endothelial cells – LECs)
by triggering VEGFR3 [18]. FGF binds to FGFR and induces the pro-
liferation and migration of ECs [19]. FGFR triggering activates mitogen
activated protein (MAPK) and phosphatidylinositol-3 (PI-3) kinases
through the adapter protein ﬁbroblast growth factor receptor substrate
(FRS2α). The latter also interacts with VEGFR2, inducing extracellular
signal-regulated kinase (ERK1/2) mediated VEGFR up-regulation, po-
tentiating VEGF-mediated ECs activation and suggesting a mechanism
of cooperation between two pathways [20,21]. In alignment with these
ﬁndings, FGF inhibition critically aﬀects VEGFA-induced angiogenesis
[22].
Another feature of tumor angiogenesis is the presence of polarized
ECs, characterized by expression of growth factor receptors (e.g. EGFR)
[23] and tumor endothelial markers (TEM) [24], up-regulation of an-
giogenic receptors and constitutive activation of survival PI3K-AKT
signaling pathway [25,26], which confer augmented proliferation, mi-
gratory and drug resistance capabilities compared to normal ECs. These
genetic and phenotypic diﬀerences result in morphological, structural
and functional abnormalities of tumor-associated blood vessels. The
abnormalities include enlarged vessels with severe branching,
multilayered and discontinuous EC alignment with defective coverage
by pericytes and basement membrane, resulting in a dysfunctional
vasculature characterized by low tissue perfusion, leakiness and poor
blood ﬂow [27].
The generation of an actively growing solid tumor mass with a high
cellular proliferative rate signiﬁcantly reduces the availability of O2,
especially for the cells found within the inner tumor core. Tumor and
stromal cells subsequently release augmented levels of pro-angiogenic
factors, especially VEGFA, angiopoietin (ANGPT) 2, and CXCL12,
driven by the activation of HIF1 [28,29]. Another consequence of re-
duced O2 availability is the metabolic change from oxidative phos-
phorylation to aerobic glycolysis, which results in dramatically en-
hanced glucose consumption and elevated accumulation of lactate with
consequent acidosis of the tumor microenvironment. These hypoxia-
dependent metabolic modiﬁcations are associated with drug resistance
and support angiogenesis at both the tumor and stromal levels. Within
tumor cells, nutrient deprivation and acidosis stabilize VEGFA mRNA
[30], whereas tumor-derived lactate supports angiogenesis and tumor
growth by activating ECs via an autocrine NF-κB-CXCL8 pathway that
promotes migration and tube formation [31] and polarizes tumor-as-
sociated macrophage (TAM) towards a proangiogenic M2-like pheno-
type [32]. CXCR4 is expressed by many cell types including leukocytes,
ECs, epithelial and cancer cells. CXCL12-CXCR4 interaction is directed
involved in chemotaxis, invasion and recruitment of ECs to neoangio-
genic niches to promote blood vessel sprouting [33]; moreover, the
CXCL12-CXCR4 axis fosters angiogenic responses by activating AKT
signaling and consequent VEGF synthesis in cancer cells [34]. Thus,
blood vessel sprouting within tumors reﬂects a process in which tumor
and stromal cells cooperate and synergize to sustain tumor growth and
invasion.
Tumor stroma is composed of two main categories of cells, classiﬁed
according to their origin surrounded by an extracellular matrix (ECM):
bone marrow-derived, tumor inﬁltrating hematopoietic cells (pre-
dominantly leukocytes), and tissue resident cells, such as ECs, pericytes,
adipocytes, ﬁbroblasts and resident macrophages. Within the tissue-
resident stromal cells, the most important angiogenic players are
cancer-associated ﬁbroblasts (CAFs) and pericytes. TGFβ-activated
CAFs participate in tumor angiogenesis by directly secreting angiogenic
factors such as VEGFA, bFGF, CXCL12 and by modifying the composi-
tion and stiﬀness of the ECM and the local interstitial pressure, col-
lectively contributing to tumor progression [35,36]. Pericytes physi-
cally surround the vessels and play a crucial role in regulating
endothelial proliferation and in promoting ECs survival and establish-
ment of tight junctions [37]. However, cancer polarized-pericytes may
support the survival of tumor blood vessels since their targeting in
combination with anti-angiogenic inhibitors improves treatment eﬃ-
cacy compared to each single agent in a preclinical model of pancreatic
islet carcinoma [38]. Within the tumor-inﬁltrating, bone marrow-de-
rived leukocyte component, TAMs, granulocytes and myeloid derived
suppressor cells (MDSCs) are the most abundant and representative
angiogenic inducers. TAMs can either support or restrict blood vessel
sprouting, according to the immune context and speciﬁc micro-
environment to which they are exposed [39]. M2-polarized TAMs in-
duce angiogenesis by directly releasing high amounts of growth factors
such as VEGFA, VEGFC, PlGF, basic ﬁbroblast growth factor (bFGF),
platelet derived growth factor β (PDGFβ), cytokines such as IL1β, or by
producing membrane-bound or soluble proteases such as cathepsins or
MMPs, which mobilize proangiogenic molecules sequestered in the
ECM and remodel it supporting EC invasion [40–42]. Moreover, TAMs
may indirectly promote angiogenesis by releasing inﬂammatory cyto-
kines (IL6, CXCL8), which support the recruitment and activation of
other myeloid subsets such as granulocytes and MDSCs [40]. Granu-
locytes and MDSCs are another main source of proangiogenic factors,
especially VEGFA, bFGF, MMP9, BV8, whose expression is up-regulated
following triggering of CSF3R and STAT3 activation [43]. In support of
neutrophil and MDSC proangiogenic role, many researchers have
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described how their depletion can correlate with impaired angiogenesis
[44,45]. Tumor-inﬁltrating MDSCs have also been shown to contribute
to tumor angiogenesis and have recently been implicated in tumor re-
sistance to anti-angiogenic therapy [46]. CSF-1 regulates the tumor-
mediated recruitment of monocytic MDSCs and pharmacologic
blockade of CSF1R inhibits angiogenesis by reducing the expression of
proangiogenic and immunosuppressive genes, restricting in vivo the
growth of 3LL lung carcinoma tumor when used in combination with
anti VEGFR2 [47]. T lymphocytes as well may either induce or impair
tumor angiogenesis according to the cytokines they produce: T helper
(Th)1 and IFNγ cytokines act directly on the endothelium by inducing
maturation of ECs and indirectly on TAMs by promoting their polar-
ization towards M1 phenotype [48,49]. In stark contrast, Th2 cytokines
support TAM skewing towards the M2 phenotype, whereas T regulatory
(Treg) lymphocytes act directly on endothelium by secreting angiogenic
factors [50], and on eﬀector and Th1 T cells, by inducing their anergy
[51]. More detailed mechanisms and players of cancer-dependent an-
giogenesis can be found elsewhere in recent reviews [52,53]; here we
focus on the functional consequences of tumor endothelial dysfunction
in ﬁne-tuning the local immune response to favor cancer progression.
1.2. Leukocyte inﬁltration and prognostic value
The ﬁeld of cancer immunotherapy began with the demonstration
that the immune system is able to recognize and eventually control
(especially in the early phase of carcinogenesis) tumor proliferation by
innate and adaptive immunity. The ﬁrst proof of concept, now widely
accepted, was provided more than one hundred years ago by Dr. Coley
who elicited tumor regression in inoperable sarcoma patients by local
injection of bacterial toxins derived from Streptococcus pyogenes and
Serratia marcescens [54]. The rationale of this approach originated from
the observation that patients with unresectable sarcoma cancer ex-
perienced tumor regression after being accidentally infected by Strep-
tococcus pyogenes; Coley hypothesized that cancer rejection was medi-
ated by host immune response reactivation directed towards tumor.
Then, other investigators provided clear preclinical and clinical evi-
dence of host immune system involvement in tumor rejection. Dr. Gross
showed that immune system can recognize spontaneous tumors induced
by a carcinogenic drug in mice [55], 22 years prior identifying the cells
involved in this process, namely T lymphocytes. Taken together, these
ﬁndings show that tumors can be viewed as antigenic, even if often
poorly immunogenic.
The vertebrate immune system is mainly divided into innate and
adaptive immune responses that together works in tight synergy to
resolve pathological situations (from pathogen infection to cancer de-
velopment). The main diﬀerence between the two immunological arms
relies in the target recognition mechanism. The innate immune re-
sponse recognizes generic foreign motifs, while the adaptive immune
response targets virtually any foreign antigen generating im-
munological memory. The innate arm of the immune system partici-
pates both as a ﬁrst line defense and in the subsequent activation of the
adaptive immune response by presenting antigens to B and T cells. Host
immune-dependent tumor restriction is mediated by the activation of
both arms of immune system; however, T lymphocytes are considered
the main players owing to their ability to recognize speciﬁc tumor
antigens, expanding in great numbers and killing antigen-expressing
cells. Nevertheless, the ability of the host immune system to trigger a
tumor-speciﬁc immune response fails to control tumor growth even-
tually, due to immune evasion strategies orchestrated by evolving tu-
mors. Notwithstanding the encouraging preclinical results of many
cancer immunotherapy approaches based on re-activating established,
low frequency tumor-speciﬁc T cells or educating the host immune
system to recognize and attack the tumor, clinical results do not reach
expectations when translated into the clinic. Contributing to this lack of
robust eﬀectiveness, treatment eﬃcacy widely varies among patients
and tumor histology [56]. Failure of standard chemotherapy and new
immunotherapy approaches is in part explained by the impaired ability
of these drugs and therapy to reach their intended target, owing to
tumor-associated blood vessel dysfunction and the action of tumor-re-
cruited stromal cells, which selectively inhibits cell inﬁltration and
edits speciﬁc leukocyte subsets [57]. The critical role of tumor en-
dothelium in either promoting or restricting the delivery of drugs and
leukocytes in the tumor bed has been described by many research
groups; the identiﬁcation of tumor-inﬁltrating lymphocytes (TIL)
within the tumor mass represents indeed a good prognostic factor for
patient survival within diﬀerent tumor types, such as colorectal [58],
ovarian [59] melanoma, renal, breast, bladder, lung, prostatic, head
and neck, lung and esophageal tumors [60]. Additionally, the compo-
sition, physical location and phenotype of CD3+ T cells have become an
important clinical attribute considered even more predictive than
standard histopathology (i.e. tumor stage) and aptly named “immuno-
score” [61]. The presence of an inﬂamed tumor with a high immuno-
score is typical of immunogenic tumors, such as melanoma. However,
about 40% of melanoma tumors do not harbor any TILs [62]. Even if
there is a positive correlation between tumor mutation load and re-
sponse to immunotherapy [63,64], higher numbers of mutations do not
guarantee higher tumor immunogenicity since an immunosuppressive
tumor microenvironment and defective antigen presentation machinery
may limit the elicitation or maintenance of a tumor-speciﬁc immune
response. Tumor endothelium directly and indirectly supports all these
mechanisms of immune evasion triggered by tumor. More speciﬁcally,
tumor endothelium plays a critical role in orchestrating the traﬃcking
of unique leukocyte subsets (including T cells). Moreover, endothelium
can directly present antigens to T cells aﬀecting their activation status.
1.3. Endothelium directs leukocyte traﬃc to cancer
Leukocytes are recruited into peripheral tissues following extra-
vasation from blood vessels; in a dysfunctional endothelial environ-
ment, such that exists in a tumor context, this process is severally im-
paired. The transmigration of leukocytes outside the vessel is a multi-
step, ﬁnely controlled procedure which includes rolling, slow rolling,
activation, adhesion strengthening, intraluminal crawling, paracellular
and transcellular migration [65]. Many molecular actors involved
during each of these phases are critical for eﬃcient transmigration.
During the rolling phase, leukocytes start interacting with ECs through
the action of selectins: leukocyte-derived L-selectins and endothelial P-
selectin bind to P-selectin glycoprotein ligand 1 (PSGL1) [66,67].
Leukocytes may interact with endothelial E-selectin through CD44 and
E-selectin ligand 1 (ESL1)[68]. PSGL1-L-selectin mediated leukocyte–-
leukocyte interactions allows the capture of leukocytes not expressing
ligands for either P or E selectins on the inﬂamed endothelium, in a
process called secondary tethering. Leukocyte adhesion is promoted by
selectin binding under normal conditions of blood ﬂow, since cells
detach when ﬂow is stopped [69]. Leukocyte interaction on en-
dothelium during rolling and adhesion steps is promoted as well by
other mechanisms, such as integrin-mediated interaction with adhesion
molecules; lymphocytes, for example, can roll via vascular cell-adhesion
molecule 1 (VCAM1) interaction with very late antigen 4 (VLA4) [70].
Similarly, lymphocyte function-associated antigen 1 (LFA1) binding to
endothelial intercellular adhesion molecule 1 (ICAM1) synergizes with
selectins in lymphocytes rolling [71] in vitro. Rolling and slow rolling
on endothelium is preliminary for leukocytes activation, which is trig-
gered by the interaction of chemokines, either released or exposed on
ECs after inﬂammatory stimuli, with cognate receptors expressed on
leukocytes and result in integrin-dependent ﬁrm adhesion. These che-
mokines bind G-protein-coupled receptor (GPCR) on leukocytes, trig-
gering an inside-outside signaling cascade that culminates with almost
instantaneous integrin activation. The signaling cascade induced by
GPCRs includes three steps: phospholipase C activation, GTPases acti-
vation and triggering of integrin structural changes through the inter-
action with actin binding proteins. For instance, CCL21, SDF,
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macrophage inﬂammatory protein (MIP3)α and MIP3β induce arrest of
rolling lymphocytes within one second under ﬂow conditions through
ICAM1 binding [72]. Platelets contribute to leukocyte activation by
depositing CCL5 and CXCL4 on endothelium [73]. Chemokines can also
synergize with leukocyte activation by heterophilic interactions; for
example CXCL4 heterophilic interactions with CCL5 ampliﬁes the ad-
hesion of monocytes to endothelium. [74]. Shulman et al. [75] de-
scribed the crucial role of activated endothelium-derived chemokines in
supporting the transendothelial migration of Th1 and cytotoxic T cells,
rather than rolling and adhesion steps. Interestingly, these chemokines
are not necessarily exposed on the EC membrane, but stored in vesicles
found beneath the plasma membrane and released during tight lym-
phocyte-endothelial synapse formation, guiding T cell migration [75].
Taken together, these observations suggest that the chemo attractant
availability on the endothelium, expression levels of chemokines re-
ceptors on leukocytes, as well the aﬃnity for their ligands, and the
downstream complex signaling cascade, all contribute and conse-
quently aﬀect leukocyte activation and adhesion to the endothelium.
Leukocyte transmigration to the periphery includes overcoming the
integrity of three barriers: endothelial cells, pericytes and the basement
membrane. Before crossing the blood vessel, leukocytes crawl on en-
dothelium seeking the best transmigration route. Strict interactions
between adhesion molecules on ECs and cognate integrins on leuko-
cytes and the association of cytoplasmic proteins trigger the generation
of docking structures that promote and initiates transendothelial mi-
gration [76]. This process can be achieved by two main routes: para-
cellular migration, which consists of leukocyte crossing along en-
dothelial cell–cell junctions and transcellular migration, in which
leukocytes cross directly through EC body. The former is promoted by
adhesion-molecule triggering, especially ICAM1, platelet endothelial
cell adhesion molecule (PECAM)1, junctional adhesion molecule (JAM)
1, CD99, and endothelial cell selective adhesion molecule (ESAM).
Transcellular migration is less common and supported by the genera-
tion of vesicuo-vacuolar organelles within ECs, which are membra-
ne–associated gateways for leukocyte crossing through the EC body
[77]. This process seems to be guided by the same adhesion molecules
involved in paracellular transmigration, such as ICAM1, and requires
the stabilization action of actin [78]. Leukocytes overcome pericytes
and basement membrane barriers in regions where their presence is less
consistent. For example, lower expression of laminin 10, collagen IV,
and nidogen-2 in untreated murine cremasteric venules were associated
with lower pericyte coverage and used as main migration routes by
neutrophils [79]. This non-disruptive transmigration route, however,
could be enhanced by inﬂammatory stimuli (such as IL1β), which en-
large these transmigration areas by lowering the amount of basement
protein coverage [79].
Given the multi-step, organization and complexity of the transmi-
gration process, it is clear that during pathological processes, such as
chronic inﬂammation and cancer, endothelium dysfunction can dra-
matically aﬀect leukocyte migration into peripheral tissues. Tumors
speciﬁcally exploit these regulatory mechanisms, such as endothelial
expression of selectins, adhesion molecules, chemokines, as well as
blood ﬂow and shear stress to establish endothelial dysfunction with
the purpose of generating a tumor microenvironment characterized by
enhanced immune privilege status.
2. Molecular insights into “endothelial anergy”
Tumor-associated blood vessels, as mentioned above, are char-
acterized by several structural and functional deviations that mirror
poor functionality and consequent poor oxygenation. Hypoxia triggers
the chronic release of proangiogenic factors, which polarize ECs thus
establishing “endothelial anergy”. This state is characterized by en-
dothelial unresponsiveness to inﬂammatory stimuli. Indeed, normal ECs
become activated following triggering by inﬂammatory cytokines (e.g.
TNFα, IFNγ, IL1) and up-regulate selectins and adhesion molecules,
which in turn promote extravasation of leukocytes into the peripheral
tissues. However, chronic endothelial stimulation with VEGF and bFGF
dramatically aﬀects this process, even in presence of TNFα [80]. Ac-
cordingly, VEGF axis blockade restores normal adhesion molecule ex-
pression and leukocyte-vessel interactions [80]. Preconditioning with
bFGF is able to prevent ICAM up-regulation following IL1 or IFNγ sti-
mulation. Both bFGF and VEGF restrict ICAM1, VCAM1, E-selectin in-
duction after TNFα challenge, whereas TGFβ pretreatment aﬀects
VCAM1 and E-selectin induction [81]. The mechanism of bFGF-medi-
ated impaired up-regulation of ICAM1 following TNFα stimulation has
been described in vitro: bFGF prevents the activation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) triggered by
TNFα by blocking the phosphorylation and degradation of IkBα (NF-κB
inhibitor) and by activating p38 MAPK [82]. Dysregulated cytokine
composition resulting in increased levels of IL4, IL10 and TGFβ are
associated with reduced adhesion molecules expression on ECs [83].
Accordingly, elevated production of these cytokines is a common fea-
ture of several tumor types [59,84,85]. Clinical data conﬁrm the ne-
gative role of proangiogenic factors in leukocyte recruitment by or-
chestrating the expression of adhesion molecules on tumor
endothelium. For example, in breast tumor, the expression of VEGFC
and VEGFD fosters bFGF down-regulation of ICAM1 on ECs [86]. Also,
in ovarian cancer, the presence of TILs inversely correlates with VEGF
levels [59]. In accordance with these results, the interruption of the
VEGF axis by antibodies targeting VEGF or VEGFR2 or by using small
molecules inhibitors of broad spectrum TKRs, such as sunitinib, sor-
afenib, and angiostatic peptides, improved leukocyte traﬃcking within
tumors, increasing TIL inﬁltration and eventually tumor restriction in
several preclinical tumor models [87–90]. Similarly, sunitinib-mediated
VEGF signaling inhibition increases the expression of endothelial
CXCL10 and CXCL11, in a NF-κB dependent manner, which results in a
18-fold higher concentration of TILs within B16 melanoma tumors
[91]. Inhibition of signaling pathways upstream of VEGF expression,
such as inhibition of RAF oncogene-driven angiogenesis, can indirectly
restore TIL inﬁltration, improving the eﬃcacy of ACT immunotherapy
in a preclinical melanoma model [92].
Epidermal growth factor like domain (EGFL) 7 is a proangiogenic
factor with unique features since it is physiologically expressed almost
exclusively by actively proliferating ECs and act in paracrine and au-
tocrine ways to support blood vessel development through Notch sig-
naling [93]. However EGFL7 is also expressed in many tumors and cell
lines and its expression levels correlates with worse prognosis and
higher tumor grade in several cancers including malignant gliomas,
hepatocellular carcinoma (HCC), and colon tumors [94–96]. EGFL7
expression is associated with decreased levels of adhesion molecules
VCAM1, ICAM1 in preclinical models of lung and breast tumors and in
breast cancer patients [97]. During acute inﬂammation, TNFα represses
endothelial expression of EGFL7 by regulating its promoter activity in a
NF-κB dependent manner. In contrast, EGFL7 maintains endothelium in
an anergic state by preventing IkBα degradation and consequently NF-
κB activation [98].
Nitric Oxide (NO) is a highly reactive free radical compound in-
volved in a number of processes. In the tumor microenvironment, NO is
often a crucial mediator of immune suppression on eﬀector T cells
[99–101]. However, NO plays a critical role in regulating blood ﬂow,
angiogenesis, and leukocyte-EC interactions [102]. NO synthase in-
hibition increases expression of E-selectin, ICAM1 and VCAM1 adhesion
molecules on ECs, which in turn mediate higher leukocyte rolling and
adhesion on endothelium [103,104]. Buckanovich and colleagues [105]
identiﬁed an NO-dependent mechanism of adhesion molecule regula-
tion and endothelial anergy triggered by the endothelin (ET) – ETBR
interaction. ETs are a family of biologically active peptides that include
ET1-4. ET1 was originally identiﬁed in venom snake and investigated
for its potent vasoconstrictor action on ECs [106]. However, ETs and
their receptors (referred as the ET axis) have been described in sup-
porting pathological conditions as well, including cancer, by promoting
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angiogenesis, vasculogenesis, proliferation, apoptosis and metastatic
dissemination of tumor cells by activating paracrine and autocrine
loops [107,108]. The ET1 axis is activated in many cancers, including
breast, ovarian, renal, lung, cervical, glioma, prostate and colon cancers
[108]. ETs bind their cognate receptors, named ETAR and ETBR, G-
protein coupled receptors that triggers opposite action on ECs. ET1 is
up-regulated both in patient-derived tumor specimens and in vitro in
several models of cancer, and is able to promote angiogenesis by sup-
porting VEGF synthesis in a HIF1-dependent manner [108,109]. ET1
binding to ETBR directly promotes angiogenesis via proliferation and
diﬀerentiation on ECs by synergizing with VEGF, and ET1 blockade
with a selective ETBR antagonist (BQ788) reverses this phenotype
[110]. The transcription proﬁling of tumor endothelium isolated from
ovarian cancer specimens (enriched by immunohistochemistry-guided
laser-capture microdissection) identiﬁed genes, including ETBR, whose
up-regulation signiﬁcantly correlates with endothelial anergy and poor
clinical outcome. The ET1 axis regulates ICAM1 expression on ECs
through the paracrine release of NO, and ETBR or NOS inhibitors can
reverse this phenotype. Accordingly, ETBR inhibition in vivo improves T
cell homing to tumor and consequently, the eﬃcacy of tumor vaccines
and adoptive cell-based immunotherapies in ovarian and lung pre-
clinical cancer models [105]. In the same transcriptional proﬁling study
of tumor endothelium isolated from ovarian cancer patients, comple-
ment component 3 (c3) up-regulation signiﬁcantly correlated with the
presence of TILs. Expanding upon these studies, ET-1-dependent en-
dothelial anergy can be reversed by transfer of adequate quantities of
tumor-reactive T cells [111]. This process requires local production of
C3, activation of the complement cascade with release of C5a, which in
turn acts on ECs to express adhesion molecules promoting T cell
transmigration [111]. Accordingly, both total and conditional C3 and
C5aR1 deﬁciencies, and pharmacological C5aR1 blockade, critically
aﬀects T cell homing to tumor, rendering ACT immunotherapy in-
eﬀective [111]. Inﬁltrating tumor-speciﬁc CD4+ and CD8+ T cells re-
lease Th1 cytokines that activate ECs, triggering expression and acti-
vation of the complement cascade, resulting in the expression of
adhesion molecules and promoting T cell inﬁltration in tumor [111].
However, the complement system is a complex component of the im-
mune response, which embraces both innate and adaptive immunity
with a clear role in ﬁne-tuning host immune defenses against patho-
gens. The complement system is viewed as a global regulator of im-
munity and tissue homeostasis with the role of the complement system
on tumor progression only beginning to be explored. A critical appraisal
of the complement system has been summarized elsewhere and is
currently envisioned having a dual function by both promoting or re-
stricting tumor progression according to the immune context
[112–114].
Soluble versions of adhesion molecules can also aﬀect leukocyte
transmigration eﬃciency by direct binding to their cognate receptors,
in competition with membrane bound versions, or indirectly by pro-
moting angiogenesis. Melanoma cell adhesion molecule (MCAM) or
CD146 is a component of endothelial junctions with a role in cellular
cohesion. It is expressed mainly by endothelial, perivascular cells and
by a multitude of tumors; accordingly, CD146 is considered a poor
prognostic marker in melanoma [115] RCC [116], and other tumors
[117]. The rationale for this association relies on the role of CD146 in
activating angiogenesis on tumor endothelium [118,119] and in sy-
nergizing with VEGF during cancer progression [120]. In accordance
with these concepts, endothelial CD146 conditional deﬁciency or
CD146 pharmacologic blockade impacts tumor growth by aﬀecting
angiogenesis [120,121]. However, tumor and ECs also produce a so-
luble version of CD146 (sCD146) with chemotactic and angiogenic
properties [118]. Selective blockade of CD146 inhibits vascularization,
growth and survival of CD146-positive tumors [122]. Endoglin is an-
other protein expressed by ECs and a marker of tumor vasculature
[123]. Endoglin interacts with VLA-5 expressed on leukocytes to pro-
mote adhesion to the endothelium. However, ECs produce an endoglin
soluble variant as well, which competes for binding to VLA5, impairing
leukocyte transmigration [124]. Interestingly, serum levels of soluble
endoglin correlates with cancer relapse and represents an early prog-
nostic factor of metastasis development in colorectal, breast and other
solid tumors [125].
Tumor endothelium can therefore express speciﬁc adhesion mole-
cules to orchestrate the extravasation of selected leukocyte subsets with
the purpose of sculpting the tumor microenvironment towards immune
suppression. The common lymphatic endothelial and vascular en-
dothelial receptor (CLEVER) 1 is a scavenging receptor constitutively
expressed on lymphatic endothelium and TIE2+ macrophages and
synthesized in ECs during inﬂammation [126]. CLEVER1 relevance in
cancer progression has been addressed in preclinical melanoma and
breast cancer models. Both CLEVER1 conditional deﬁciency in an en-
dothelial or macrophage context and selective antibody blockade in
wild type mice reduce the accumulation of immune suppressive subsets
(Treg and TAM) in breast and melanoma tumors, which in turn sig-
niﬁcantly reduces tumor progression [127]. In some cases, augmented
expression of addressins on tumor endothelium can be responsible for
preferential transmigration of Treg lymphocytes. Human pancreatic
carcinoma endothelium up-regulates mucosal adressin cell adhesion
molecule 1 (MAdCAM1), VCAM1, CD62E and CD166, which interact
with their ligands β7 integrin (binding to MAdCAM1 and VCAM1),
CD62L (binding to E-selectin, MAdCAM1, and VCAM1) and CD166
(homophilic binding to CD166) exposed on Tregs, promoting their ex-
travasation [128]. Disrupting these interactions by selective blocking
antibodies critically impacts the eﬃciency of Treg transmigration
through tumor-associated endothelium compared to other T cell subsets
[128].
3. Angiogenic-derived mechanical dysfunction
3.1. Shear stress and ECM stiﬀness
As previously described, tumor-associated blood vessels are char-
acterized by irregular morphology and structure that reﬂect poor
functionality, reduced ﬂow, and leakage compared to normal blood
vessels. Shear stress is a mechanical force that acts on ECs through
CD31 and VE-cadherin and has an important role in regulating en-
dothelial functions. High interstitial pressure and reduced blood ﬂow
within tumor blood vessels reduce shear stress and impair the rolling
and adhesion of leukocytes on endothelium [69]. However, reduced
blood ﬂow also aﬀects the expression of endothelial selectins and ad-
hesion molecules exacerbating impairment of transmigration [129].
Finally, ECM composition contributes to endothelial dysfunction. ECM
is composed of glycoproteins, proteoglycans and polysaccharides and
regulates many cellular functions such as metabolism, proliferation,
migration and survival by generating an environment with speciﬁc
biochemical, physical and biomechanical properties [130]. Tumor-de-
rived ECM is characterized by an elevated rigidness that reﬂects higher
interstitial pressure due to tumor proliferation, cytoarchitecture mod-
iﬁcation of cancer cells, ECM composition and ﬁbrosis [131]. Tumor
and stromal cells react to ECM stiﬀness by integrin-mediated, me-
chanosensing structures. ECs may sense ECM stiﬀness as well. In vitro
studies showed that hard substrates impair endothelial monolayer
function compared to soft substrates, independent from inﬂammatory
signals [132].
Vessel structure and function is deeply inﬂuenced by pericytes that
physiologically and structurally surround ECs in the vasculature.
Pericytes and vasculature mutually regulate each other. Activated and
proliferating ECs promote pericyte recruitment by releasing PDGFB and
expressing ANGPT receptor TIE2. Secreted PDGFB is anchored on ECs
membrane and on ECM generating a chemical gradient which guides
pericyte and vascular smooth muscle cells (vSMCs) chemoattraction
towards EC [133]. Pericyte recruitment on sprouting blood vessel is
supported by pericyte-derived ANGPT1 binding to endothelial TIE2
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marker and by pericyte-derived NG2 proteoglycan [134]. Pericyte-EC
interaction results in sprout stabilization by secretion of TIMPs, in-
hibition of proliferation, induction of survival and vessel maturation
through ANGPT1-TIE2 binding [135,136]. During cancer progression
though, ECs disrupt this molecular network in response to ANGPT2 up-
regulation which competes with ANGPT1 for binding to TIE2 and by
associating preferentially with TIE2+ TAMs [137] which establishes a
positive angiogenic stimulation loop with ECs [138]. However, peri-
cytes may also support angiogenesis since inhibition of PDGFR sig-
naling can lead to tumor blood vessel regression [139] underscoring a
pivotal role pericytes play in promoting EC survival [140]. Dis-
appointing results from clinical trials targeting PDGFR axis as single
agent suggest that pericytes are not crucial elements in regulating vessel
function. Other strategies that aim to enforce pericyte-ECs interaction
by simultaneously antagonizing ANGPT2 and activating TIE2 showed
tumor blood vessels normalization and increased perfusion, resulting in
increased chemotherapy delivery and reduced tumor growth and me-
tastasis in preclinical models of glioma, breast and lung cancers [141].
Cumulatively, these results support the concept that the presence of
dysfunctional, irregularly branched and leaky blood vessels inversely
correlates with the presence of TILs and that ﬂuid extravasation does
not contribute to T cell inﬁltration in the tumor bed. This observation is
the result of dysregulation in the physiological and ﬁnely-tuned me-
chanical and molecular mechanisms of leukocyte-endothelium inter-
actions and transmigration.
Hypoxia also drives the production and release of lymphangiogenic
factors as well, speciﬁcally VEGFC and VEGFD, which promote the
generation of new lymphatic vessels within tumor and, in turn, are
associated with greater probability of metastatic dissemination, relapse
and poor clinical outcome [142]. In this context, high interstitial ﬂuid
in solid tumors increases activation and secretion of TGFβ by CAFs
thereby promoting local immune tolerance. Additionally, it increases
also lymph drainage to adjacent lymph nodes where tumor-secreted
factors and immature antigen presenting cells (APCs), such as immature
dendritic cells – iDCs, previously exposed to tumor microenvironment,
are recruited and activate naïve T cells in a tolerogenic manner to
promote peripheral tolerance [143,144].
4. Mechanisms of endothelium-mediated direct regulation of
immune response
Transmigration is the principal and most characterized blood vessel-
mediated mechanism that regulates the immune response. However,
ECs may promote or impact T cell activation through several other
strategies. ECs are peripheral, semiprofessional, non-hematopoietic
APCs [145]. ECs constitutively express major histocompatibility com-
plex (MHC) class I and II molecules, which can be up-regulated fol-
lowing inﬂammatory stimuli. ECs express antigen processing ma-
chinery, adhesion proteins, cytokines and co-stimulatory and co-
inhibitory surface molecules such as CD137, CD40, OX40L, inducible T-
cell costimulator ligand (ICOSL), programmed death ligand (PD-L)1,
PD-L2, FASL, TNF-related apoptosis-inducing ligand (TRAIL). However,
they do not express CD80 and CD86 costimulatory molecules which
explains why ECs cannot prime naïve T cells like professional APCs but
only stimulate antigen-experienced T cells [146]. The balance between
stimulating and inhibiting surface molecule expression deﬁnes T cell
fate and tumors exploit this ﬁnely-tuned process to promote local im-
mune dysfunction. FASL upregulation on tumor endothelium mediated
by tumor-secreted VEGFA, IL10 and PGE2, has been associated with
signiﬁcantly lower CD8+/Treg ratio inﬁltration in human ovarian,
breast prostate colon, bladder, renal cancers. This immune escape me-
chanism is promoted by endothelial, FASL-dependent selective apop-
tosis of eﬀector T cells (but not Treg). VEGF or PGE2 pharmacological
blockade restored eﬀector T cell inﬁltration and tumor growth control
by down-regulation of FASL on tumor endothelium [147]. Both tumor
blood and lymphatic ECs can express B7-H1 (PD-L1), which is up-
regulated under inﬂammatory conditions to refrain T cell activation
[148,149]. PD-L1 belongs to the B7-family proteins and binds to PD-1
on activated lymphocytes to negatively control T cell activation. In a
tumor context, PD-L1 induces peripheral (LEC) or local (EC) tolerance
of tumor speciﬁc T cells [150,151] and pharmacological blockade of
PD-1 axis increases endothelial cell co-stimulation of PHA-activated
CD8+ T cells in vitro [149]. B7-H3 and B7-H4 are inhibitory proteins
related to the B7 family whose expression on tumor endothelium cor-
relates with poor outcome in ovarian [152], renal cell [153,154] can-
cers. ECs express CD137 and its engagement activates ECs to produce
adhesion molecules and co-stimulate T cell activity. However, cancer
cells counteract this interaction by producing a soluble version of
CD137 (sCD137), which antagonizes the membrane bound version of
the receptor preventing T cell co-stimulation [155].
Additionally, ECs can interfere with T cell function by releasing
soluble factors, especially cytokines, angiogenic factors [156], and
immunomodulatory enzymes [157]. By releasing IL15, ECs may induce
T cell proliferation and promote transmigration. IL15 derived from
activated and resting umbilical vein ECs triggers and supports LFA1
integrin and CD69 up-regulation in T cells in vitro and in human
rheumatoid arthritis in vivo preclinical models, respectively [158].
Moreover ECs can secrete IL6 in response to inﬂammatory stimuli
skewing CD4+ T cell polarization towards Th17 and Treg responses.
This EC capability has been investigated in an allogenic model of mi-
crovascular endothelium (HMEC) and requires IL6 secretion and ICAM
up-regulation in activated ECs to polarize CD4+ T cell towards Th17
and Treg, respectively [159]. Preclinical in vitro functional studies re-
veal that tumor endothelial-dependent release of VEGF, PGE2, TGFβ
and IL6 can promote T cell anergy, as well as reduce NK activity and
macrophage phagocytosis [160]. Finally, ECs can produce enzymes
such as endothelial nitric oxide synthase (eNOS), arginase and in-
doleamine 2,3-dioxygenase (IDO), which have direct negative im-
munoregulatory properties on T cells by depleting L-arginine and L-
tryptophan amino acids [161]. IDO-dependent, DC-mediated T cell
suppression is considered a potent tumor immunoevasion mechanism
but its role in the endothelial context is less clear. Endothelial expres-
sion of IDO can promote endothelial tube formation and angiogenesis
[162]. In renal cell carcinoma, endothelial-derived IDO seems to impair
tumor cell proliferation and progression since its expression positively
correlates with improved prognosis [162]. The mechanisms of tumor
endothelium-mediated immune dysfunction are summarized in Fig. 1:
the expression of endothelium-associated molecules (shown in red font)
is modiﬁed by tumor-derived factors (listed in yellow ﬁlled squares),
resulting in impairment of immune cell migration and increase of im-
munosuppression.
5. Clinical implications of current anti-angiogenic therapies
Given the paramount role of angiogenesis in tumor progression,
several therapeutic approaches targeting VEGF binding to their re-
ceptors or their activation status have been developed and tested in
preclinical and clinical settings. Cancer anti-angiogenic therapy began
with neutralizing VEGF antibody in preclinical models demonstrating in
vivo tumor growth suppression [163]. Importantly, this tumor in-
hibitory eﬀect relies on tumor vessel restriction rather than direct
toxicity on tumor cells. Clinical trials using VEGF-blocking antibody
bevacizumab for metastatic RCC patients [164] and subsequently for
metastatic breast and prostate cancer patients [165] showed clinical
beneﬁt. Accordingly, bevacizumab combined with chemotherapy de-
monstrated encouraging clinical results improving overall survival for
colorectal carcinoma patients [166]. Other therapeutic approaches
targeting the VEGF-VEGFR axis soon afterwards were developed, such
as VEGF2R-directed antibody or small molecule multi target inhibitors
such as TKRs.
Since the demonstration of the antitumor eﬀectiveness of bev-
acizumab, this antibody-dependent angiogenic blockade has been
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Fig. 1. Immune regulatory properties of tumor-associated endothelium. The demand for greater nutrient and oxygen supply activates a hypoxic response within tumors that initiates
and sustains the angiogenic switch. Tumor-secreted angiogenic factors and inﬂammatory cytokines (in yellow) act on tumor endothelium to regulate either directly (A) or indirectly (B)
the expression of adhesion molecules and vessel functionality, which in turn aﬀects and selects T cell extravasation in the tumor bed. Moreover, ECs regulate T cell activation and ﬁtness
(C) by modulating the expression of co-stimulatory and co-inhibitory molecules or by up-regulating enzymes that aﬀect T cell metabolism.
Fig. 2. Targeting of tumor blood vessels restores endothelium function. Pharmacological blockade of the angiogenic axis restores adhesion molecule expression on endothelium and
induces vessel normalization that promotes T cell migration within the tumor. Immune checkpoint inhibition can synergize with anti-angiogenic therapy by unleashing the cytotoxic
potential of eﬀector T cells.
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approved for several other advanced malignancies, such as glio-
blastoma, RCC, ovarian, lung, breast, gastric and cervical cancer, often
in combination with chemotherapy [167]. The clinical rationale for
combining anti-angiogenic drugs with chemotherapy relies on the me-
chanism of action of anti-VEGFA therapy, which directly reduces tumor
growth rate rather than inducing tumor regression [168]. Secondly,
VEGFA blockade generates pruning of newly-formed and immature
blood vessels (such as tumor-induced vessels) rather than established
and stabilized blood vessels. This observation suggests anti-VEGF-de-
pendent “normalization” on tumor vessels may consequently improve
perfusion and extravasation of chemotherapeutic agents and immune
cells within the tumor bed [169] (Fig. 2). Although a probable ex-
planation for the observed increased eﬃcacy of chemotherapy in
combination with anti VEGFA blockade, a deﬁnitive demonstration is
lacking for anti-VEGF-dependent, augmented accumulation of drugs
within tumors of patients.
Another debated point is whether anti-angiogenic therapies can
unleash metastatic progression. This observation relies on the modest
clinical results that anti-angiogenic therapy is achieving in overall
survival beneﬁt rather than progression free survival compared to
preclinical studies [170]. One explanation is that preclinical and clin-
ical settings are quite diﬀerent. Mouse experiments are performed on
localized primary tumor whereas phase 2 and 3 clinical trials are car-
ried out on patients with late stage metastatic tumors so it is diﬃcult to
predict overall survival eﬃcacy before entering the clinic. Moreover,
many tumor-targeting therapies (such as radiation or chemotherapy)
limit tumor progression but potentially increase pro-metastatic poten-
tial of cancer cells [170]. Tumor relapse and metastasis after initial
tumor response have been extensively reported for anti-angiogenic
therapies as well [171]. Moreover, as with many types of cancer
treatments, it is very diﬃcult to predict which patients will beneﬁt on
anti-angiogenic therapies; indirect impact of antiangiogenesis therapy
on other tumor compartments of the immune system may compensate
and bypass VEGFA blockade. Indeed, myeloid cells, especially MDSCs
and TAMs, foster angiogenesis by VEGF dependent and independent
mechanisms [49,99] and their targeting increases sensitivity to anti-
angiogenic therapy [172–174]. On the other hand, anti-angiogenic
therapy can enhance cancer immunotherapy strategies by aﬀecting
tumor-induced endothelial immune suppression. In accordance with
this hypothesis, many research teams combine anti-angiogenic therapy
with immunotherapy in preclinical models with encouraging results,
supporting their translation to the clinic [175]. The combination of
anti-angiogenic therapy with passive T cell administration or active
tumor cell vaccination can improve T cell inﬁltration within tumor,
delaying tumor growth and increasing survival in melanoma [90] colon
[176] and breast cancer models [88,177].
Another successful preclinical approach to inhibit tumor angiogen-
esis and restore host immune function against tumor relies on educating
the immune system to recognize and destroy tumor vasculature. This
was demonstrated by employing a DNA vaccine strategy coding for
endosialin (TEM1) fused to a minimized domain of the C fragment of
tetanus toxoid (TT) [178]. TEM1 is a protein expressed on tumor blood
vessels, tumor vessel-associated pericytes, tumor-associated myoﬁbro-
blasts and tumor cells [178]. This strategy has several advantages;
TEM1 is expressed on vessels of tumors with diﬀerent histologies,
which are more accessible to eﬀector T cells, less prone to evade im-
mune system or to evolve compared to tumor cells. Both prophylactic
and therapeutic DNA vaccination with TEM1-TT was able to elicit a T
cell response against tumor endothelium, which reduced tumor vascu-
lature, increased T cell inﬁltration and aﬀected tumor growth in colon
and lung cancer models [179]. Interestingly, TEM1-TT vaccination is
able to trigger a CD8+ T cell response against tumor-speciﬁc antigens
(epitope spreading) without impairing the angiogenic physiological
processes [179]. Other preclinical approaches of tumor endothelial
CD8+ T cell-dependent targeting have been tested exploiting geneti-
cally engineered T cells with chimeric antigen receptors recognizing
VEGFR2 [180,181] and resulted in tumor growth inhibition and overall
increase in survival in diﬀerent tumor types. From a translational point
of view, many clinicians are aiming at reversing angiogenic-dependent
endothelial anergy to improve T cell inﬁltration in tumor and reactivate
those T cells with checkpoint inhibitor blockade. Although most of
these studies are still in early clinical trials, preliminary results are
encouraging. In melanoma, the combination of bevacizumab with ipi-
limumab reverts endothelial anergy on tumor endothelium by up-reg-
ulating adhesion molecules E-selectin, ICAM1, and VCAM1, which re-
sults in higher TIL in tumor bed [182] and better clinical outcome.
Higher TIL are induced as well in RCC patients after combined bev-
acizumab and atezolizumab therapy, which are associated with in-
creased T eﬀector markers, CX3CL1 and Th1 cytokine production
within tumors. Taken together, these data suggest a mutual synergy of
action between anti-angiogenic and checkpoint inhibitor blockade that
can result in superior anti-tumor eﬃcacy and clinical beneﬁt for pa-
tients [183].
6. Conclusions
In this review, we highlighted the role of the tumor endothelium in
sculpting immune responses contributing to the generation of a loca-
lized immune privileged microenvironment necessary for tumor out-
growth and spread to distal body organs. From this point of view, many
anti-angiogenic strategies signiﬁcantly reduce and/or inhibit tumor-
derived blood vessel proliferation and/or growth improving overall
survival. These treatments delay tumor growth rates rather than
causing tumor shrinkage [184] and clinicians and researchers question
which piece of the puzzle is missing. Preclinical and clinical research
has already provided some answers such as angiogenic factor re-
dundancy [185] and compensatory mechanisms triggered by the re-
cruitment of suppressive myeloid cells [46]. However, the complexity
of tumor microenvironment remains unresolved in it detailed in-
tricacies; tumors of diﬀerent histology are generally characterized by
abundant angiogenesis (hallmarks of cancer), yet even within the same
histological classiﬁcation, tumor progression and survival changes ac-
cording to the immune system’s ability to recognize and kill tumor cells
as well as by immune evading strategies. Thorough characterization of
the tumor microenvironment and increased understanding of tumor-
promoted immunosuppressive mechanisms will provide more answers
as well as more questions. Improving the molecular knowledge of tu-
mors is the ﬁrst step on this route. Many factors other than endothelial
anergy may aﬀect T cell inﬁltration and function, tumor fate and
clinical outcome, such as the chemokine and cytokine milieu within the
tumor microenvironment. For example, hypoxia-driven secretion of
CCL28 promotes T-reg recruitment [50], while CX3CL1 (fractalkine)
increases T cell homing to tumors [186], and these chemokines are
considered negative and positive prognostic factors, respectively. Cy-
tokines directly limit or stimulate T cell function and polarize both T
lymphocytes and myeloid cells in a tumor-promoting or tumor-re-
stricting manner [187]. Even the same molecule or pathway may in-
duce positive or negative eﬀects on immunity, depending on the cel-
lular context; CCL2 promotes both recruitment of T cells and monocytic
MDSCs and its post translational modiﬁcations induced by reactive
nitrogen species (RNS) results in dysfunctional homing of T cells in
favor of monocytic MDSCs [188]. HIF1α can be considered a main
driver of angiogenesis. However, HIF1α and VEGFA expression in
CD8+ T cells drives their tumor inﬁltration and cytotoxic properties,
whereas their absence increases tumorigenesis. Moreover, an inverse
correlation was found between VEGFA expression and CD8+ T cell
inﬁltration in breast cancer patients, suggesting yet another mechanism
of angiogenic regulation of immunity [189]. According to this study,
classic histological classiﬁcation of tumors is considered obsolete and
clinicians should start thinking more in terms of molecular classiﬁca-
tion (genetic ﬁngerprinting) and the tumor immune context rather than
tumor type and grade. For example, the genomic analysis of 456
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pancreatic ductal adenocarcinomas (PDACs) deﬁned 4 PDAC subtypes
which drive diﬀerent evolution and clinical outcome [190]. Accord-
ingly, another group unveiled the role of speciﬁc genetic alterations in
combination with the loss of suppressor gene Pten in deﬁning tumor
progression and stromal cell composition in prostate cancer. Surpris-
ingly, Pten loss or in combination with Trp53, Zbtb7a or Pml mutations,
generated tumors with totally diﬀerent immune inﬁltrates ranging from
“cold” (non-inﬂamed tumor) to deeply inﬂamed and heavily leukocyte
inﬁltrated tumors [191]. Tumor genetic instability and somatic muta-
tions may trigger T cell responses against neoantigens [192,193] that
can be fostered by immune checkpoint inhibition therapy. However,
even in the case of highly immunogenic melanoma, not all patients
respond equally to checkpoint inhibition therapy. Lastly, the nature of
mutations can distinguish tumor fate. In support of this hypothesis, a
genetic mutational analysis performed on 10,000 human tissues from
30 diﬀerent cancer types classiﬁed tumors into two types according to
the kind of mutation: mutator-type associated with response to im-
munotherapy and chromosome instable, which is associated with im-
munoevasion [194]. Thus, genotypic and immunophenotypic char-
acterization may improve patient stratiﬁcation and move the current
treatment paradigm one step forward towards patient-tailored anti-
cancer therapy. Understanding the molecular circuitry and major
players for diﬀerent histologically distinct tumor types that contribute
to tumor endothelial dysfunction with the aim of reversing the tumor
endothelial anergic state is a lofty goal and carries high potential for
development of novel therapeutic strategies that target the tumor en-
dothelium.
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